Trial
NCT04685499
Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Weill Medical College of Cornell University
Collaborators
Oncolys BioPharma Inc
Condition
Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
Intervention
OBP-301
Why stopped
This study was terminated due to low participant enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-11